Fred Hutchinson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fred Hutchinson Cancer Center sits in the top decile of US sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count).
Fred Hutchinson Cancer Center: 483 sponsored US clinical trials, 57 recruiting.
Fred Hutchinson Cancer Center sponsors 483 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 327 completed. 27 of these trials are in Phase 3-4 (later-stage) and 304 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 10 trials.
Top-decile sponsor footprint
Fred Hutchinson Cancer Center ranks in the top decile of sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
327 of 391 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
483 total, page 5 of 10
TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02180698
Blood Samples to Identify Biomarkers of Busulfan
NCT02291965
SmartQuit Program for Smoking Cessation
NCT04510077
Cancer Communication Within Hispanic Social Networks
NCT04444232
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
NCT02466061
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
NCT01858740
Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)
NCT01812278
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
NCT02044796
MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance
NCT01936441
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
NCT01523821
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
NCT01921387
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
NCT01957709
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT01961115
CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01881867
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
NCT01807182
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
NCT01812252
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
NCT01929408
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
NCT01865617
INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant
NCT01602211
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01804101
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01831232
Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant
NCT01758484
Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI
NCT03434561
Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)
NCT01812070
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
NCT01758458
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
NCT01729845
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
NCT01640301
Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant
NCT01236885
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
NCT01930981
FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health
NCT01619020
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
NCT01527045
Glucosamine and Chondroitin Effects
NCT01682694
Crohn's Allogeneic Transplant Study
NCT01570348
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
NCT01607645
Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
NCT01616056
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT01567059
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
NCT01525407
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
NCT01419795
CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
NCT01475058
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
NCT01339663
Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy
NCT01525420
Gene Therapy for Fanconi Anemia
NCT01331018
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01503242
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
NCT01300572
Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
NCT01477021
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT01434472
Vitamin D and Adipose Tissue Inflammation
NCT01477034
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
NCT01418209
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
NCT01465386
COMIDAS Comparing Original Mexican Diets and Standard US Diets
NCT01369173
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 144 |
| Phase 2 | 160 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Fred Hutchinson Cancer Center pipeline
57 recruiting of 483 indexed (12% open); 327 completed (68%).
Phase mix: 27 late (III/IV) vs 304 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fred Hutchinson Cancer Center: open-pipeline peers nationwide
Peers matched on 483 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Fred Hutchinson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 483 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Fred Hutchinson Cancer Center page
483 registered trials is a research-attention snapshot, not an endorsement of Fred Hutchinson Cancer Center or any single study.
- 57 of Fred Hutchinson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Fred Hutchinson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fred Hutchinson Cancer Center pipeline card: 483 registered trials from official public datasets.Report a data error.